Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based Upon Current Assumptions, Of ~$30M

Author: Benzinga Newsdesk | July 25, 2024 04:36pm

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature

 

- Company anticipates annualized capital and workforce requirements to be reduced by approximately 25 percent

 

BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the strategic prioritization of its autoimmune programs and organizational restructuring to strengthen operational efficiencies while enabling its encouraging oncology survival data to continue to mature.

Posted In: CUE